A panel of advisers to the Food and Drug Administration will meet this week to make recommendations on whether specialized pharmacies should be allowed to make some popular wellness peptides.

The committee will discuss whether compounding pharmacies can make the peptides in question. But FDA scientists say there’s little — if any — evidence they work in humans.

As regulators weigh whether pharmacies can legally compound wellness peptides, companies are preparing for a repeat of the GLP-1 boom—only this time with even murkier science.

A FDA advisory committee will review evidence surrounding peptides. Experts are concerned there is a paucity of evidence to back their approval for legal compounding.

A panel of advisers to the Food and Drug Administration will meet this week to make recommendations on whether specialized pharmacies should be allowed to make some popular…

With an FDA panel expected to recommend legal production of as many as seven peptides this week, compounding pharmacies and telehealth companies are preparing for the coming…

An FDA panel is reviewing seven peptides for potential approval, sparking concerns about their widespread use in compounding pharmacies and the gray market.

U.S. FDA advisers this week will weigh whether seven popular peptides can be compounded by licensed pharmacies, but even if regulators decline to expand access, industry…

A little-known advisory group to the US Food and Drug Administration will meet this week to mull over whether to ease restrictions on certain peptides. The injectables are popular…

FDA has questioned the evidence as demand surges for the compounds promoted for sleep, muscle growth, and anti-ageing.

Federal health advisers are meeting to review a group of controversial chemicals called peptides